According to Bloomberg, KKR (KKR.US) and Warburg Pincus (a private equity fund) are planning to acquire the German company Gerresheimer. The German manufacturer of pharmaceutical and cosmetic packaging has seen an increase of nearly 13% since the beginning of the year, bringing its market capitalization to approximately €2.74 billion. As a result of the reports, KKR is up more than 3% today.
The official confirmation by Gerresheimer in February regarding interest from private equity funds in a potential acquisition drove the stock price up by over 18% from its roughly two-year lows. The company's declines in 2024 have contributed to increased private equity activity, particularly considering the diversification of Gerresheimer's two main business lines. The cosmetics segment focuses on plastic packaging and glass perfume bottles, while the pharmaceuticals segment is centered on more complex products such as infusion devices and inhalers.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThe potential acquisition of the company by the KKR and Warburg Pincus conglomerate remains speculative, as neither company has officially confirmed the deal. However, it is worth noting that the movement in Gerresheimer's stock is supported by takeover speculation, meaning that an official announcement from KKR or Warburg Pincus could trigger another price move.
Gerresheimer's stock has rebounded more than 18% from this year's lows. Source: xStation
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
